Stability and plasmatic protein binding of novel zidovudine prodrugs: Targeting site ii of human serum albumin

Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework

Obesity is a growing global health concern associated with high comorbidity rates, leading to an increasing number of patients who are obese requiring medication. However, clinical trials often exclude or under-represent individuals who are obese, creating the need for a methodology to adjust labeling to ensure safe and effective dosing for all patients. To address this, we developed a 2-part decision tree framework to prioritize drugs for dedicated pharmacokinetic studies in obese subjects. Leveraging current drug knowledge and modeling techniques, the decision tree system predicts expected exposure changes and recommends labeling strategies, allowing stakeholders to prioritize resources toward the drugs most in need. In a case study evaluating 30 drugs from literature across different therapeutic areas, our first decision tree predicted the expected direction of exposure change accurately in 73% of cases. We conclude that this decision tree system offers a valuable tool to advance research in obesity pharmacology and personalize drug development for patients who are obese, ensuring safe and effective medication.

Marine sponge-derived/inspired drugs and their applications in drug delivery systems

Oceans harbor a vast biodiversity that is not represented in terrestrial habitats. Marine sponges have been the richest source of marine natural products reported to date, and sponge-derived natural products have served as inspiration for the development of several drugs in clinical use. However, many promising sponge-derived drug candidates have been stalled in clinical trials due to lack of efficacy, off-target toxicity, metabolic instability or poor pharmacokinetics. One possible solution to this high clinical failure rate is to design drug delivery systems that deliver drugs in a controlled and specific manner. This review critically analyzes drugs/drug candidates inspired by sponge natural products and the potential use of drug delivery systems as a new strategy to enhance the success rate for translation into clinical use.

Enhanced bioaccumulation of fluorinated antibiotics in crucian carp (Carassius carassius): Influence of fluorine substituent

The negative impact of residual fluorinated antibiotics on the ecosystem and human health are of great concern. However, only a few studies have been conducted on the factors that influence the bioaccumulation of fluorinated antibiotics in aquatic organisms. To investigate the effects of fluorine substituent, environmental concentration of antibiotics, and temperature on the bioaccumulation of florfenicol (FLO), thiamphenicol (TAP), ofloxacin (OFX), and pipemidic acid (PPA), crucian carp (Carassius carassius) were exposed to different concentrations of antibiotics and different temperatures for 21 days. The liver exhibited the highest antibiotic concentrations, with 315.4 ± 13.6 ng g^-1 wet weight (ww), followed by the bile (279.4 ± 12.4 ng mL^-1), muscle (53.1 ± 4.3 ng g^-1 ww), and gills (37.1 ± 2.6 ng g^-1 ww). The FLO and OFX containing the fluorine substituent were much easier to accumulate in crucian carp compared with their isonomic TAP and PPA, respectively. The fluorine substituent increased the bioaccumulation of the targeted antibiotics in crucian carp. In addition, the lower levels of antibiotics presented higher bioaccumulation potential, but the temperature had little effect on the bioaccumulation. These findings in the present study can provide further insight into the environmental behaviors and ecological risks of fluorinated antibiotics in the aquatic environment.

Reverse Transcriptase Inhibitors Nanosystems Designed for Drug Stability and Controlled Delivery

An in-depth analysis of nanotechnology applications for the improvement of solubility, distribution, bioavailability and stability of reverse transcriptase inhibitors is reported. Current clinically used nucleoside and non-nucleoside agents, included in combination therapies, were examined in the present survey, as drugs belonging to these classes are the major component of highly active antiretroviral treatments. The inclusion of such agents into supramolecular vesicular systems, such as liposomes, niosomes and lipid solid NPs, overcomes several drawbacks related to the action of these drugs, including drug instability and unfavorable pharmacokinetics. Overall results reported in the literature show that the performances of these drugs could be significantly improved by inclusion into nanosystems.